Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDP 305 PK in Hepatic Impairment
NCT03207425Phase 1Completed
- Sponsor
- Enanta Pharmaceuticals
- Start
- Jun 2017
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of EDP-305 in Nonalcoholic steatohepatitis (NASH) (3 arms), sponsored by Enanta Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration at 216 hours, Area Under the Curve from time zero to infinity at 216 hours and 2 more. Started Jun 2017; status: completed.
02
Drugs
EDP-305
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03207425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03207425.